Human Insulin Market By Product Types (Basal or Long-acting Insulins (Lantus, Levemir, Toujeo, Tresiba, and Basagla), Bolus or Fast-acting Insulins (NovoRapid/Novolog, Humalog, Apidra, FIASP, and Admelog), Traditional Human Insulins (Novolin/Actrapid/Insulatard, and Humulin, Insuman), Combination Insulins (NovoMix, Ryzodeg, Xultophy, and Soliqua/Suliqua), and Biosimilar Insulins (Insulin Glargine Biosimilars, and Human Insulin Biosimilars)) and By Region - Trends, Analysis and Forecast till 2030

Report Code: PMI390320 | Publish Date: August 2023 | No. of Pages: 163

Global Human Insulin Market Market Companies

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Sanofi
  • Biocon
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Adocia
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Wockhardt
  • GlaxoSmithKline

Recent News:

  • In October 2023, Novo Nordisk, a Denmark-based pharmaceutical company, is preparing to conduct phase III trials of its latest insulin injection, IcoSema, in India. The Drug Controller General of India (DCGI) has commissioned the company to evaluate the effectiveness and safety of this new drug, which is specifically designed to regulate blood sugar levels in people diagnosed with diabetes, type 2 diabetes.
  • In March 2023, Eli Lilly announces a significant reduction in insulin delivery. Eli Lilly and Company has revealed plans to introduce a biosimilar version of insulin glargine, called Rezvoglar